Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Continous treatment with bevacizumab in elderly patients with mCRC: an open label, single arm, prospective phase IV trial to evaluate outcome and safety of continuous bevacizumab treatment in combination with chemotherapy over disease progression

Next Previous
Search
Trial Profile

Continous treatment with bevacizumab in elderly patients with mCRC: an open label, single arm, prospective phase IV trial to evaluate outcome and safety of continuous bevacizumab treatment in combination with chemotherapy over disease progression

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 20 Dec 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine; Fluorouracil
  • Indications Carcinoma; Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms GRACE

    • Most Recent Events

    • 20 Dec 2019 Status changed from suspended to discontinued.
    • 09 Jan 2019 The trial has been suspended in sweden.
    • 01 Jan 2017 Trial design published in the Clinical Practice Journal.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top